Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular Age Related Macular Degeneration (AMD)

The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.

Key Inclusion criteria:

• Patients with visual impairment due to neovascular AMD
• A qualifying vision score at study entry Key Exclusion criteria
• Active infection or inflammation either eye at study entry
• Uncontrolled glaucoma in either eye
• Any disorder in the study eye which may affect vision
• Use of any systemic anti-vascular endothelial growth factor (VEGF)-drugs within 3 months prior to study entry
• Previous treatment of the study eye for wet AMD
• Any surgery in the study eye 3 months prior to or planned with 6 month after study entry